医学临床研究
  2025年4月4日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (7): 995-997    DOI: 10.3969/j.issn.1671-7171.2023.07.010
  论著 本期目录 | 过刊浏览 | 高级检索 |
老年CHB患者PD-1、PD-L1表达情况及其与T淋巴细胞的相关性
李彤1, 孙园园2
1.新乡市第四人民医院,河南 新乡 453000;
2.新乡市第二人民医院,河南 新乡 453000
The Expression of PD-1 and PD-L1 in Elderly CHB Patients and their Correlation with T Lymphocyte Function
LI TONG, SUN Yuan-yuan
The Fourth Hospital of Xinxiang, Xinxiang Henan 453000
全文: PDF (1179 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨老年慢性乙型肝炎(CHB)患者外周血中程序性细胞死亡蛋白-1(PD-1)及其配体(PD-L1)表达情况及其与T淋巴细胞的相关性。【方法】选取2020年3月至2021年4月两院收治86例老年CHB患者(观察组),根据其病情严重程度将其分为轻度组(n=41)、中度组(n=32)、重度组(n=13)。所有患者均接受恩替卡韦治疗,依据治疗48周后是否获得完全应答分为获得组(n=39)、未获得组(n=47)。比较观察组和对照组PD-1、PD-L1水平及T淋巴细胞(CD3+、CD4+、CD8+、CD4+/CD8+)。分析观察组PD-1、PD-L1水平与T淋巴细胞、病情严重程度相关性,采用受试者工作特征(ROC)曲线分析PD-1、PD-L1对完全应答的预测价值。【结果】与对照组比较,观察组CD3+、CD4+、CD4+/CD8+降低,PD-1、PD-L1、CD8+升高(P<0.05)。重度组、中度组、轻度组T细胞中PD-1、PD-L1水平呈降低趋势(P<0.05)。PD-1、PD-L1水平与CD3+、CD4+、CD4+/CD8+呈负相关,且与CD8+、病情严重程度呈正相关(P<0.05)。获得组患者PD-1、PD-L1水平低于未获得组,差异有统计学意义(P<0.05)。ROC曲线结果显示,PD-1、PD-L1对老年CHB患者抗病毒治疗的临床疗效具有一定预测价值(P<0.05)。【结论】老年CHB患者T细胞中PD-1、PD-L1水平升高,且与T淋巴细胞功能密切相关,可间接评估CHB病情进展,且对患者的抗病毒疗效具有较高预测价值。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
李彤
孙园园
关键词 乙型肝炎, 慢性程序性细胞死亡受体1T淋巴细胞老年人    
Abstract:【Objective】 To investigate the expression of Programmed cell death protein-1 (PD-1) and its ligand (PD-L1) in the peripheral blood of elderly patients with chronic hepatitis B (CHB) and their correlation with T lymphocytes. 【Methods】A total of 86 elderly CHB patients (observation group) admitted to two hospitals from March 2020 to April 2021 were selected and divided into mild group (n=41), moderate group (n=32), and severe group (n=13) based on their severity. All patients were treated with Entecavir, and were divided into the acquired group (n=39) and the non acquired group (n=47) according to whether they received complete response after 48 weeks of treatment. The levels of PD-1, PD-L1, and T lymphocytes (CD3+, CD4+, CD8+, CD4+/CD8+) were compared between the observation group and the control group. We analyzed the correlation between the levels of PD-1 and PD-L1 in the study group and T lymphocytes, as well as the severity of the disease. ROC analysis was conducted to assess the predictive value of PD-1 and PD-L1 for complete response.【Results】Compared with the control group, the observation group showed a decrease in CD3+, CD4+, CD4+/CD8+, while PD-1, PD-L1, and CD8+increased (P<0.05). The levels of PD-1 and PD-L1 in T cells of the severe, moderate, and mild groups showed a decreasing trend (P<0.05). The levels of PD-1 and PD-L1 were negatively correlated with CD3+, CD4+, CD4+/CD8+, and positively correlated with CD8+and disease severity (P<0.05). The levels of PD-1 and PD-L1 in the acquired group were lower than those in the non acquired group, and the difference was statistically significant (P<0.05). The results of Receiver operating characteristic showed that PD-1 and PD-L1 had a certain predictive value for the clinical efficacy of antiviral therapy in elderly CHB patients (P<0.05). 【Conclusion】 The levels of PD-1 and PD-L1 in T cells of elderly CHB patients are elevated and closely related to T lymphocyte function, which can indirectly evaluate the progression of CHB and have high predictive value for the antiviral efficacy of patients.
Key wordsHepatitis B, Chronic    Programmed Cell Death 1 Receptor    T-Lymphocytes    Aged
收稿日期: 2022-07-29     
中图分类号:  R512.62  
引用本文:   
李彤, 孙园园. 老年CHB患者PD-1、PD-L1表达情况及其与T淋巴细胞的相关性[J]. 医学临床研究, 2023, 40(7): 995-997.
LI TONG, SUN Yuan-yuan. The Expression of PD-1 and PD-L1 in Elderly CHB Patients and their Correlation with T Lymphocyte Function. JOURNAL OF CLINICAL RESEARCH, 2023, 40(7): 995-997.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.07.010     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I7/995
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn